Sixty-one Bordetella pertussis isolates were tested blindly in two laboratories to determine their serotype nature by monoclonal antibodies using two independent methods: the standard bacterial microagglutination assay and an indirect whole-cell enzyme-linked immunosorbent assay. Both methods gave concordant results in 60 of the 61 isolates.
Sixty-one Bordetella pertussis isolates were tested blindly in two laboratories to determine their serotype nature by monoclonal antibodies using two independent methods: the standard bacterial microagglutination assay and an indirect whole-cell enzyme-linked immunosorbent assay. Both methods gave concordant results in 60 of the 61 isolates.
Many methods have been described for distinguishing strains of Bordetella pertussis, and these range from the traditional method of serotyping (3) to the more sophisticated genetic methods such as pulsed-field gel electrophoresis (2, 5, 6) , ribotyping (13) , randomly amplified polymorphic DNA (8) , and multilocus sequence typing (14) . Undoubtedly the more sensitive DNA methods are highly discriminative in distinguishing many strains of B. pertussis into different fingerprints or sequence types. Serotyping results, on the other hand, may vary within the same profile. Moreover serotype seems to change with population immunity, and serotyping has provided data to suggest that immunity towards whooping cough depends on the serotype specificity of the pertussis bacteria (12) . This was evident when vaccines lacking one serotype given to a population resulted in pertussis cases caused by strains of the serotype not present in the vaccine preparation (4, 11, 15) . In 1979, the World Health Organization recommended that whole-cell pertussis vaccine should contain both serotype 2 and 3 antigens (16) . Therefore, together with the more sensitive DNA methods, serotyping continues to be a useful laboratory surveillance tool for studying the epidemiology of pertussis.
Based on reactions with specific antisera, B. pertussis can be divided into three types: serotype 2, serotype 3, and serotype 2,3. The major serotyping antigens of B. pertussis have been determined to be associated with their fimbriae. Traditionally serotyping is done by the bacterial agglutination test using the slide agglutination method with bacteria mixed with specific serotyping antisera on glass slides. Hybridoma monoclonal antibodies to the serotype 2 and serotype 3 fimbria antigens have also been produced and characterized (7) . Attempts to standardize the serotyping method by means of microagglutination have also been made and published (9) . Nevertheless, the bacterial agglutination method is still subjective and depends on the ability of the bacteria to form a smooth suspension. Therefore, we have explored the possibility of using an objective method of indirect whole-cell ELISA for the serotyping of B. pertussis isolates. This assay development was evaluated independently at two laboratories with strains of B. pertussis that had been serotyped by the microagglutination method in one laboratory and then tested blindly in a second laboratory by the indirect whole-cell ELISA using different batches of the same serotyping monoclonal antibodies. In this communication, we report our findings and compare the two methods for the determination of serotypes of B. pertussis isolates.
B. pertussis isolates used in this study were mostly from the culture collection of the Swedish Institute for Infectious Disease Control (SIIDC) and were selected to represent isolates from different periods as well as expressing different serotyping antigens of Fim2, Fim3, and Fim2,3. All isolates were retyped before they were sent blindly to the National Microbiology Laboratory (NML) for testing by ELISA. A few Canadian patient isolates were typed by ELISA at NML and sent blindly to SIIDC for testing by the bacterial microagglutination assay.
Monoclonal antibodies that recognize serotype 2 and 3 fimbria antigens were made from hybridoma cell lines BPF2 (antiFim2) and BPC10 (anti-Fim3), which were originally developed by Brennan, Manclark, and Li (November 1992; U.S. patent 5,162,223) (7). Antibodies from the hybridoma cell lines were produced at the National Institute of Biological Standards and Control and made available to NML and SIIDC.
Serotyping of isolates by the bacterial microagglutination method was done as essentially described by Mooi et al. (9) . Traditional slide agglutination was carried out according to the method described by Preston (10) . Indirect whole-cell ELISA was done according to a procedure described for the serotyp- a Eight of the strains listed here were also studied at the NIBSC by whole-cell ELISA using the same set of monoclonal antibodies, but antigens, buffers, enzyme conjugate, and substrate were their own in-house reagents. Basically the same ELISA results were obtained at NIBSC, which were further confirmed by their traditional slide agglutination test.
b Although a cutoff value in the optical density (OD) of the ELISA method was not set before this study, all ELISA-positive isolates showed ODs of Ն0.8, while ELISA-negative isolates had ODs of Ͻ0.2. MAb, monoclonal antibody.
c Control strains expressing only Fim2 antigen (strain 2558) or Fim3 antigen (strain Hav) were included in each assay, and the optical densities given in this table for these two strains were representative data. Although day-to-day variations occurred, the margin of difference between the positive and negative strains was wide enough that no indeterminate values were encountered during the numerous assays performed for the method development evaluation stage. ϩve, positive.
ing of meningococci (1) . Briefly, a smooth suspension of a loopful of bacteria grown for 48 h on a Bordet-Gengou agar plate was prepared in pH 7.4 sterile phosphate-buffered saline and heat inactivated at 56°C for 1 hour. The inactivated bacterial suspension was cooled and stored at 4°C until ready for testing. Such inactivated cell suspensions for the ELISA were found to be stable at 4°C for months and can be reused as antigens (e.g., as controls) in multiple assays. Antigen coating was done by adding 100 l per well of the inactivated B. pertussis bacterial antigen, diluted in phosphate-buffered saline to give an optical density of about 0.1 at 620 nm, to a Nunc Maxisorp 96-well flat-bottomed Immuno microtiter plate (Nalge Nunc International, Rochester, NY). Detection of binding of the serotyping monoclonal antibodies to the bacterial cells was done by addition of a 1:5,000 dilution of horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G F(abЈ) 2 fragment-specific antibodies (Jackson ImmunoResearch Laboratories, Inc., West Grove, Pa.). Each assay was done in the presence of both a Fim2-positive control strain and a Fim3-positive control strain. Details of the different serological methods are available from the authors.
Optimal dilutions of the anti-Fim2 and anti-Fim3 monoclonal antibodies for use in the indirect whole-cell ELISA were determined by titration of each antibody against Fim2-positive and Fim3-positive reference strains. A dilution of 1:1,000 was chosen for both antibodies in subsequent ELISAs for the serotyping of B. pertussis isolates.
Out of the 54 Swedish isolates tested blindly by the indirect whole-cell ELISA method, 53 (98%) gave concordant results with the bacterial microagglutination method (Table 1) . Of these 53 Swedish isolates that gave concordant results with both methods, 23 were serotype 2, 26 were serotype 3, and 4 were serotype 2,3. The only isolate that gave a discordant result was an isolate that was found to be serotype 3 by bacterial microagglutination but that was identified as serotype 2,3 by indirect whole-cell ELISA. This strain was retyped by both laboratories, and the results did not change. Potential reasons for this discrepant result may include the following. The microagglutination test was done on bacteria grown on charcoal agar plates for 72 h while the indirect ELISA was done on antigens prepared from cells grown for 48 h on Bordet-Gengou agar plates. Cells grown under different conditions may have different expression of their fimbria antigens (e.g., cells grown on charcoal agar may express only Fim3 antigen, or the Fim2 antigens may be expressed at low quantities or different qualities or at a subsurface location and therefore not be accessible to antibodies).
To further evaluate the ELISA method, eight Canadian isolates expressing the Fim3 antigens as determined by ELISA along with the single Swedish isolate that did not provide a matching result were sent blindly from NML to the SIIDC for testing by bacterial microagglutination. All eight Canadian isolates gave identical results regardless of the method of testing used, but the single Swedish isolate still tested as serotype 3 by the bacterial agglutination method but was typed as serotype 2,3 by ELISA.
Our data presented here show that the indirect whole-cell ELISA method for serotyping of B. pertussis is at least as good as the bacterial microagglutination assay (9) . Several advantages of the indirect whole-cell ELISA method may make it a potentially attractive alternative method for serotyping pertussis strains. These advantages may include the method's objectivity and reproducibility and use of very small amounts of antibodies as well as its suitability for screening large numbers of strains. Therefore, based on this preliminary result, we propose to further evaluate and validate this method for the routine serotyping of B. pertussis in an interlaboratory trial involving several laboratories. Such studies may also involve the exchange of antigen preparations by different participating laboratories to compare antigenic presentation in cells prepared under different laboratory conditions, including the type of medium used to grow the bacteria, as well as to allow different laboratories to test the same batch of cells or antigens.
